VOLITIONRX LTD
VNRX · XNYSCIK 93314fmd_0MTC270Z0KKGVDS647M94QJSDDManufacturing · In Vitro & In Vivo Diagnostic SubstancesTemplate: Standard
Coverage: Jan 01, 2011 to Sep 30, 2026, 63 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | 0 | 0 | 0 | 0 | 1 | 1 | 2 |
| Research and development | 8 | 8 | 11 | 10 | 15 | 13 | 15 | 20 | 14 | 10 |
| Selling, general and administrative | 5 | 7 | 7 | 6 | 7 | 15 | 17 | 17 | 14 | 13 |
| Total operating expenses | 12 | 15 | 18 | 16 | 21 | 28 | 32 | 37 | 28 | 23 |
| Operating income | (12) | (15) | (18) | (16) | (21) | (28) | (32) | (36) | (27) | (22) |
| Interest expense | 0 | 0 | (0) | 0 | 0 | 0 | – | – | – | – |
| Other non-operating income (expense) | – | – | (0) | (0) | 1 | 1 | 1 | 0 | (0) | (2) |
| Income tax expense | – | – | – | – | – | – | – | – | – | – |
| Net income from continuing operations | – | – | – | (16) | (20) | (27) | – | – | – | – |
| Net income | (12) | (15) | (18) | (16) | (20) | (27) | (31) | (36) | (27) | (23) |
| Net income to common shareholders | – | – | – | – | – | – | – | (35) | (27) | – |